Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review : American Journal of Clinical Oncology

Secondary Logo

Journal Logo

Original Articles: Thoracic

Trimodality Treatment of Malignant Pleural Mesothelioma

An Institutional Review

Kapeles, Matthew BS*; Gensheimer, Michael F. MD*; Mart, Dylan A. MD; Sottero, Theo L. BS*; Kusano, Aaron S. MD*; Truong, Anh MD; Farjah, Farhood MD*; Laramore, George E. MD, PhD*; Stelzer, Keith J. MD, PhD§; Patel, Shilpen A. MD*

Author Information
American Journal of Clinical Oncology 41(1):p 30-35, January 2018. | DOI: 10.1097/COC.0000000000000225



Malignant pleural mesothelioma (MPM) is a deadly disease with varying treatment options. This study retrospectively describes treatment practices at the University of Washington Medical System from 1980 to 2011, and evaluates the impact of trimodality therapy and radiation (photon and neutron) on survival.


A retrospective study was conducted on patients treated for MPM. Univariate and multivariate methods were utilized to evaluate potential factors associated with survival. Treatments received and baseline characteristics were included. Survival analysis of trimodality therapy was performed using a propensity score method to control for baseline characteristics.


Among 78 eligible patients, the median age at diagnosis was 59 years and the median survival was 13.7 months. On multivariate analysis, the significant predictors of improved survival were age, smoking history, location, and receipt of radiation therapy or chemotherapy. In the 48 patients receiving radiation therapy, the difference in survival between neutron therapy and non-neutron therapy patients was not statistically significant: hazard ratio, 1.20 (95% confidence interval, 0.68-2.13), P=0.52. Patients receiving trimodality therapy were more likely to have early-stage disease (60% vs. 30%) and epithelioid histology (86% vs. 58%). In a propensity score-weighted Cox proportional hazards model, trimodality therapy patients had improved overall survival, hazard ratio 0.45, P=0.004, median 14.6 versus 8.6 months.


Trimodality therapy was significantly associated with prolonged survival in patients with MPM, even when adjusting for baseline patient factors. Radiation therapy was associated with improved survival, but the modality of radiation therapy used was not associated with outcome.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

You can read the full text of this article if you:

Access through Ovid